Programs & products

First clinical activity data of the combination of monalizumab and cetuximab New preclinical data further supporting the rationale of Innate’s first- or best-in-class antibodies Eric Vivier, Chief...

Innate Pharma presents a clinical update on its broad and diverse development portfolio of first- or best-in-class antibodies in immuno-oncology Update on the development program with AstraZeneca on...

Lirilumab continues to be well-tolerated in monotherapy and in combination across multiple tumor indications in an exploratory clinical program with partner Bristol-Myers Squibb The combination of...

Cash, cash equivalents and financial assets* for the Company amounted to €204.1m (million euros) as of June 30, 2017 Significant clinical progress within the period: Dose-escalation data of the...

IPH5401, an anti-C5aR antibody, potentially reverses tumor immuno-suppressive microenvironment and overcomes tumor resistance; preclinical data suggest that combined C5aR and PD-1 blockade...

Oral presentation on the dose-escalation part of a Phase I trial at the International Conference on Malignant Lymphoma (ICML) in Lugano; IPH4102 was evaluated in elderly and heavily pretreated...

Anti-C5a receptor (C5aR) is a first-in-class clinical-stage monoclonal antibody (mAb) targeting myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment; Innate Pharma...

Complete safety results and updated clinical activity data will be presented at the ICML 2017 in Lugano in June; Preparation for cohort expansion part is ongoing. Innate Pharma SA (the “Company” -...

Increased scope to explore additional cohorts of Opdivo (nivolumab) plus lirilumab in solid tumors, including a cohort exploring Opdivo with or without lirilumab in squamous cell carcinoma of the head...

Reinforcing safety profile of monalizumab and rationale for broad ability to combine with other anticancer agents Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces...